ecancermedicalscience

Clinical Study

Repurposing drugs in oncology (ReDO)—Cimetidine as an anti-cancer agent

26 Nov 2014
Pan Pantziarka, Gauthier Bouche, Lydie Meheus, Vidula Sukhatme, Vikas P Sukhatme

Cimetidine, the first H2 receptor antagonist in widespread clinical use, has anti-cancer properties that have been elucidated in a broad range of pre-clinical and clinical studies for a number of different cancer types. These data are summarised and discussed in relation to a number of distinct mechanisms of action. Based on the evidence presented, it is proposed that cimetidine would synergise with a range of other drugs, including existing chemotherapeutics, and that further exploration of the potential of cimetidine as an anti-cancer therapeutic is warranted. Furthermore, there is compelling evidence that cimetidine administration during the peri-operative period may provide a survival benefit in some cancers. A number of possible combinations with other drugs are discussed in the supplementary material accompanying this paper.

Related Articles

Joaquin Fernandez-Alberti, Matías Mihura Irribarra, Agustín Rancati, Nicolas Panzardi, Maria Florencia Cora, Daniela Speisky, Daniel Enrique Pirchi
Annie Kanchan Baa, Sameer Rastogi, Sanal Fernandes, Shakti Shrivastava, Rajni Yadav, Adarsh Barwad, Shamim A Shamim, Nihar Ranjan Dash
Juan Francisco Olivos-Gonzales, Elily Apumayta-Requena, Andrés Guevara-Jabiles, Mercedes Bravo-Taxa
Rodrigo Motta Guerrero, Veronica Arnao Labajos, Sophia Lozano Ballena, Carlos Aliaga Macha, Miguel Sotelo Lezama, Cristian Pacheco Roman, Paola Montenegro Beltran, Alejandro Figueroa Torrejon